SK Biopharmaceuticals Co Ltd
326030
Company Profile
Business description
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in the research and development of new drugs for the treatment of central nervous system (CNS) disorders. The company is also researching the development of drugs to treat brain tumors, including metastatic tumors. Its drug pipeline includes Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and more.
Contact
221, Pangyoyeok-ro
Bundang-gu
Gyeonggi-do
Seongnam13494
KORT: +82 3180930114
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
269
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 78.80 | -0.87% |
| CAC 40 | 8,205.76 | 5.74 | -0.07% |
| DAX 40 | 24,953.42 | 84.73 | 0.34% |
| Dow JONES (US) | 48,977.18 | 594.79 | 1.23% |
| FTSE 100 | 10,107.30 | 102.73 | 1.03% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,395.82 | 160.19 | 0.69% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,902.05 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,682.80 | 88.50 | -1.01% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |